pply sensors or active antibacterial/viral devices.Peptide-based materials are emerging as smart building blocks for nanobiodevices due to the programmability of their properties via the molecular constituents or arrangements. Many clever molecular self-assembly approaches have been devised to produce peptide crystalline structures. However, their freeform shaping remains a challenge due to the intrinsic self-assembly nature. Here, we report the fabrication of freeform, crystalline diphenylalanine (FF) peptide structures by combining meniscus-guided 3D printing with molecular self-assembly. Self-assembly in 3D-printed FF arises from mild thermal activation under precise temperature control of the build platform. After thorough characterizations, we demonstrate layer-by-layer, crystalline 3D printing with a high spatial resolution of 2 μm laterally and 200 nm vertically. The 3D-printed FF exhibits piezoelectricity originating from its crystalline character, showing the potential to become a key constituent for bioelectronic devices. We expect this technique to open up the possibility to create functional devices based on self-assembled organic materials without design restrictions.A kind of N, P, C, O-containing polymer was easily prepared via microwave heating of phytic acid and thiourea just for 90 s. After impregnation and reduction of H2PdCl4, highly dispersed Pd single atoms/sub-nano clusters loaded on the phytic acid/thiourea polymer (Pd-CNSP) were successfully obtained. Owing to the synergetic effect of the polymer support and Pd, the catalyst Pd-CNSP achieves a great atomic efficiency of Pd species and exhibits an outstanding catalytic ability in the reduction of 4-nitrophenol. The k value of the catalyst Pd-CNSP (2.17 min-1 mg-1) is about 19 times higher than that of the commercial Pd/C (5 wt %) catalyst. The turnover frequency value is as high as 848 min-1, which is the highest value reported so far. Pd-CNSP also has good selectivity for the reduction of halogen-substituted (Cl and Br) nitroaromatics. It is expected to be mass-produced and used in other industrial hydrogenation reactions.Nanocomposites containing FeS as catalyst and MoS2 as cocatalyst have been synthesized toward efficient heterogeneous Fenton reaction. The deposition of FeS nanoparticles in situ on the surface of MoS2 nanosheets creates strong contact between the two components and generates a large number of exposed Mo6+ sites and sulfur vacancies, which contribute to the enhanced degradation rate by accelerating Fe3+/Fe2+ cycling and ensuring rapid electron transfer. In addition, the MoS2/FeS nanocomposite catalysts exhibit the best performance at near-neutral conditions (pH 6.5), which solves the challenges in conventional Fenton reactions such as leaching of metal ions, the formation of iron slurry, and the need of adjusting solution pH. Further, the nanocomposite can maintain high efficiency after many recycling experiments. It is believed that the MoS2/FeS nanocomposite represents an efficient heterogeneous Fenton catalyst that can greatly promote the performance of advanced oxidation processes (AOPs) for solving practical environmental issues.Infection with SARS-CoV2 leads to COVID-19, the severity of which derives from the host’s immune response, especially the release of a storm of pro-inflammatory cytokines. This coronavirus infects by first binding to the ectoenzyme Angiotensin Converting Enzyme 2 (ACE2), a serine protease acting as the receptor, while another serine protease is necessary for priming the viral spike “S” protein required for entering the cells.  https://www.selleckchem.com/products/l-arginine-l-glutamate.html  Repurposing existing drugs for potential anti-coronavirus activity have failed. As a result, there were intense efforts to rapidly produce ways of providing prophylactic active immunization (vaccines) or abortive passive (convalescent plasma or monoclonal antibodies) neutralizing antibodies. The availability of vaccines for COVID-19 have been largely successful, but many questions still remain unanswered. In spite of the original enthusiasm, clinical studies using convalescent serum or monoclonal antibodies have shown limited benefit. Moreover, the emergence of Long-COVID syndrome in most infected patients necessitates the development of treatment approaches that may prevent viral entry by blocking both serine proteases involved, as with a liposomal blend of the natural flavonoids luteolin and quercetin.Endoscopic ultrasound-guided biliary drainage has been developed as an alternative method for biliary drainage. EUS-guided hepaticogastrostomy (EUS-HGS) can be attempted via the trans-gastric route. These procedures are technically complex for two reasons. First, puncture of the intrahepatic bile duct via the trans-gastric route can be more difficult than that by other approaches because of the small diameter of the target site, and guidewire insertion or manipulation is challenging during EUS-HGS. Second, critical adverse events, such as stent migration into the abdominal cavity, could occur because of the greater mobility of the stomach compared to the duodenum. Therefore, endoscopists should be cautious when performing EUS-HGS. An advantage of EUS-HGS is that it can be performed in patients with complications such as duodenal bulb obstruction or surgically altered anatomy. Recent advances in technique and improvements in devices and stents for EUS-HGS have shown promise for improving the technical success rate of EUS-HGS and reducing the rate of adverse events. However, endoscopists should remain aware of the possibility of critical adverse events such as stent migration.Gene drive research is progressing towards future field evaluation of modified mosquitoes for malaria control in sub-Saharan Africa. While many literature sources and guidance point to the inadequacy of individual informed consent for any genetically modified mosquito release, including gene drive ones, (outside of epidemiological studies that might require blood samples) and at the need for a community-level decision, researchers often find themselves with no specific guidance on how that decision should be made, expressed and by whom. Target Malaria, the Kenya Medical Research Institute and the Pan African Mosquito Control Association co-organised a workshop with researchers and practitioners on this topic to question the model proposed by Target Malaria in its research so far that involved the release of genetically modified sterile male mosquitoes and how this could be adapted to future studies involving gene drive mosquito releases for them to offer reflections about potential best practices. This paper shares the outcomes of that workshop and highlights the remaining topics for discussion before a comprehensive model can be designed.